This year’s seminar is now available
Click to view the upcoming seminar
With the passage of the 2018 Agriculture Improvement Act (“2018 Farm Bill”), hemp and its extracts, derivatives and cannabinoids were removed from the shackles of the Controlled Substances Act on January 1, 2019, and consumer demand for cannabidiol (CBD) products is skyrocketing. However, the U.S. Food & Drug Administration’s (FDA’s) guidance position that CBD may not be marketed as a dietary supplement or food additive due to the investigation and subsequent approval of CBD as a drug is causing significant legal and regulatory confusion within States, while illicit and substandard manufacturers exploit this confusion. But rigorous regulatory frameworks of course do exist for the labeling, current good manufacturing practices, and marketing of dietary supplements and food, and entities engaged in these businesses in the U.S. are obligated to comply with those standards. This seminar will explore the impact of the 2018 Farm Bill, the Investigational New Drug preclusion within the Food, Drug & Cosmetic Act, isolate versus full-spectrum extract, the FDA’s authority and progress, and the manner in which Washington, Oregon, and certain other States are regulating CBD. We will also explore federal regulation surrounding the labeling, manufacturing, and marketing of CBD products being manufactured and sold in the U.S., including cosmetics and pet food.
Click this link to listen to the Hemp Baron’s podcast about Hemp and The Seminar Group featuring our Program Chair, Joy Beckerman.
BACK TO TOP